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Take home message: Vasopressin has similar 28-day mortality to norepinephrine but a 
different side effect profile (more digital ischaemia, fewer 
arrhythmias). We found no clear evidence for differential 
subgroup effects.
3ABSTRACT 
Purpose 
We performed an individual patient data meta-analysis to investigate the possible benefits and harms of 
vasopressin therapy in adults with septic shock both overall and in pre-defined subgroups. 
Methods 
Our pre-specified study protocol is published on PROSPERO, CRD42017071698. We identified 
randomised clinical trials up to January 2019 investigating vasopressin therapy versus any other 
vasoactive comparator in adults with septic shock. Individual patient data from each trial were 
compiled. Conventional two-stage meta-analyses were performed as well as one-stage regression 
models with single treatment covariate interactions for subgroup analyses.  
Results 
Four trials were included with a total of 1,453 patients. For the primary outcomes, there was no effect 
of vasopressin on 28-day mortality (relative risk (RR) 0.98, 95% CI 0.86 to 1.12) or serious adverse events 
(RR 1.02, 95% CI 0.82 to 1.26). Vasopressin led to more digital ischaemia (absolute risk difference (ARD) 
1.7%, 95% CI 0.3% to 3.2%) but fewer arrhythmias (ARD -2.8%, 95% CI -0.2% to -5.3%). Mesenteric 
ischaemia and acute coronary syndrome events were similar between groups. Vasopressin reduced the 
requirement for renal replacement therapy (RRT) (RR 0.86, 95% CI 0.74 to 0.99) but this finding was not 
robust to sensitivity analyses. There were no statistically significant interactions in the pre-defined 
subgroups (baseline kidney injury severity, baseline lactate, baseline norepinephrine requirement and 
time to study inclusion).  
Conclusions 
Vasopressin therapy in septic shock had no effect on 28-day mortality although the confidence intervals 
are wide. It appears safe but with a different side effect profile to norepinephrine. The finding on 
4reduced RRT should be interpreted cautiously. Future trials should focus on long term outcomes in 
select patient groups as well as incorporating cost effectiveness analyses with regard to possible 
reduced RRT use. 
5INTRODUCTION
Vasopressor therapy is used in septic shock to increase vascular resistance, raise mean arterial pressure 
and maintain perfusion of critical body tissues and organ systems [1]. The traditional approach involves 
using catecholamines but these are associated with risks including myocardial ischaemia and 
tachycardia with beta-agonists [1, 2]. These adverse effects have led to interest in adjunctive 
therapeutic strategies. 
In shock states vasopressin acts as a potent vasoconstrictor via V1a receptors on vascular smooth 
muscle [3]. A relative deficiency of vasopressin in septic shock has been described [4] and administration 
of exogenous vasopressin reduces catecholamine requirements with the hypothesis that it may 
therefore also diminish the likelihood of catecholamine related side effects. Furthermore vasopressin 
may have additional benefits in terms of organ perfusion, due to the distribution of the family of 
vasopressin receptors in different vascular beds, and additional immunological effects compared to 
norepinephrine [5]. 
The Vasopressin and Septic Shock Trial (VASST) was the first large randomised comparison of 
vasopressin with norepinephrine [6]. Although there was no significant mortality benefit to addition of 
low dose vasopressin in the overall population, there was a lower mortality in the subgroup of patients 
with less severe shock (<15 μg/min norepinephrine). Subsequent post-hoc analyses and other studies 
suggested a potential reduction in renal dysfunction with higher dose vasopressin, [7-9] as well as a 
potentially synergistic interaction with corticosteroid treatment [10, 11]. This was specifically 
investigated in the Vasopressin versus Norepinephrine as Initial Therapy in Septic Shock (VANISH) trial 
which found that early vasopressin use compared to norepinephrine did not increase the number of 
renal failure-free days and there was no interaction with corticosteroids [12]. However, the investigators 
6noted that the confidence interval for renal-failure free days included a potentially clinically relevant 
benefit for vasopressin, as well as a reduced use of renal replacement therapy (RRT). 
Although trials have not demonstrated a clear benefit for vasopressin, it is uncertain whether particular 
subgroups of patients benefit from this treatment. In particular, the following subgroups: duration of 
shock before receiving therapy, severity of shock by lactate level or by norepinephrine requirement and 
severity of kidney injury. The Surviving Sepsis Campaign 2016 guidelines use the totality of evidence to 
date to recommend low dose vasopressin as a potential adjunctive vasopressor to norepinephrine [13].  
Individual patient data (IPD) meta-analyses are considered the gold standard for synthesising 
information from RCTs [14]. They provide a means to explore further some of the aforementioned 
uncertainties around the possibility of different effects for different subgroups, and to standardise the 
analysis of outcomes. The provision of the IPD increases statistical power for investigating differential 
treatment effects [15]. Therefore, the aim of this study was to use IPD meta-analyses to quantify the 
efficacy and safety of vasopressin therapy within RCTs for septic shock, both overall and in a priori
defined subgroups. We hypothesised that there might be beneficial effects of vasopressin therapy in 
specific sub-groups despite the overall outcomes reported thus far by large trials. 
7METHODS 
The protocol for this study was published in the online PROSPERO database (CRD42017071698) prior to 
the analysis. The protocol is available at:  
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017071698  
This manuscript has been prepared in line with the guidelines by the PRISMA-IPD group and a checklist 
is available with the Supplementary Appendix [16]. 
Trial identification, selection and acquisition of data 
We performed a comprehensive search using MeSH and free-text terms for various forms of the terms 
‘septic shock’ and ‘vasopressin’, including specific drug names. The exact search strategy is listed in 
Appendix 1 of the study protocol. The following electronic databases were searched from inception to 
January 2019: MEDLINE, Embase, Science Citation Index Expanded, Cochrane Central Register of 
Controlled Trials, Clinicaltrials.gov and the World Health Organization International Clinical Trials 
Registry Platform (WHO ICTRP) search portal. Additional articles or abstracts were retrieved by manually 
scrutinising the reference list of relevant publications. There were no restrictions on language. We also 
searched conference abstracts from major critical care conferences for the last 3 years (full details in 
study protocol). 
Publications were selected for review if they satisfied the following inclusion criteria: non-crossover 
randomised controlled trial, human adults with septic shock requiring vasopressor therapy (as defined 
by the trial investigators or the International Consensus definitions for Sepsis (1992, 2001, 2016)), 
intervention (vasopressin) versus any other vasoactive comparator with minimum duration for therapy 
of three hours and/or until ICU discharge.  
8After removal of clearly irrelevant records, two authors (MN, ACG) independently screened abstracts for 
potentially eligible studies. Full text reports were then assessed for eligibility. Where there was not 
enough information to make a decision on inclusion from published information, study authors were 
contacted for further details.  Authors of eligible studies were invited to supply anonymised individual 
patient datasets. The variables requested of authors are detailed in Appendix 2 of our study protocol. 
Risk of bias was assessed by applying the Cochrane Risk of Bias tool (performed by MN, who was not 
involved in the conduct of any included studies) [17]. 
Our primary efficacy outcome was mortality at day 28 and our primary safety outcome was total 
number of serious adverse events (SAEs). Secondary outcomes included rates of use of RRT (in patients 
without end stage renal failure), duration of RRT, duration of shock, duration of ventilation, renal failure 
free days to day 28, shock free days to day 28, ventilation free days to day 28, ICU free days to day 28, 
long term mortality (maximum follow up day 60-180), ICU length of stay and hospital length of stay. For 
duration of time outcomes results were also reported for survivors and non-survivors separately due to 
the competing risk of death. 
Statistical analysis 
We estimated the overall intervention effects and generated forest plots using a conventional two-stage 
approach (trial summary measures that are then combined by standard meta-analytical methods) [18]. 
For dichotomous outcomes such as proportion dead at day 28, we used the numbers of events and 
patients to calculate the risk ratio. For continuous outcomes such as length of stay, we used the mean 
and standard deviation to calculate the mean difference. These estimates were then combined in a 
fixed-effect model (Mantel-Haenszel method) that stratified by trial. Although some continuous data 
9may not be normally distributed, this was explored in a sensitivity analysis (see below) and no variables 
were transformed for the main analysis. 
We planned to assess the following a priori defined subgroups: early versus late onset of shock to study 
inclusion (early defined as ≤12 hours, late defined as >12 hours), low versus high baseline vasopressor 
requirement (low defined as <15 μg of norepinephrine per minute or equivalent, high defined as ≥15 
μg), low versus high baseline lactate (low defined as lactate level ≤ 2mmol/l, high defined as >2mmol/l), 
low versus high severity of acute kidney injury at baseline (low defined as no acute kidney injury (AKI) 
and stage 1 AKI [19] or Risk (RIFLE criteria) [20], high defined as stage 2 & 3 AKI [19] or Injury & Failure 
(RIFLE criteria) [20]) and studies considered low versus high trial risk of bias (low defined as all domains 
judged at low risk, high defined as any domain judged at unclear or high risk).  
To explore the effect of patient characteristics on outcomes, we fitted one-stage regression models with 
single treatment covariate interactions. Three specifications of model were assessed as detailed in the 
Addendum to Tables S4-S7 in the supplementary Appendix. Model fit was compared using the Akaike 
information criterion (AIC) [21]. 
We also planned sensitivity analyses to assess the impact of not transforming skewed data to 
approximate normality (see Addendum to Table S8 in the supplementary Appendix for further details) 
and to assess for model robustness through both one- and two-stage models with either trial fixed or 
trial random-effects approaches. No adjustments were made for multiple comparisons and this should 
be kept in mind when interpreting 95% confidence intervals for secondary outcomes. All analyses were 
performed in Stata SE version 12.1 (College Station, TX).  
10
RESULTS
The electronic search was performed initially in July 2017 and then updated to January 2019. It yielded 
5,952 records in total for further assessment (see figure S1 in the supplementary Appendix). There were 
no extra records identified by conference abstract searching that were not already selected in the 
electronic search. After screening, 21 full text records were assessed of which 10 were excluded 
immediately. Reasons for exclusion of full text records are detailed in Figure S1 in the supplementary 
Appendix. Authors for all 11 potentially includable studies were contacted to determine full eligibility 
and obtain IPD. Two replies confirmed that no outcomes of interest had been collected and these 
studies were then excluded [22, 23]. Owing to a lack of replies from five studies, only four remained for 
inclusion in the analysis [6, 12, 24, 25]. 
The samples from four of the five unavailable studies [8, 26-28] were relatively small (median 30 
patients, range 23 to 42) but the trial by Oliveira et al. had a sample size of 387 [29]. However, there was 
no public protocol, no entry in a trial registry and no peer-reviewed manuscript for this trial (only two 
abstracts dating from 2011 and 2014). All five non-included studies were rated overall at high risk of bias 
(see Table S1 in the supplementary appendix for risk of bias assessment for all nine potentially 
includable studies). The three trials VASST (n=779), VANISH (n=409) and VANCS II (n=250) were rated at 
low risk of bias in all domains. The trial by Dunser et al. (n=15) was rated overall at high risk of bias. 
Individual patient data were available for these four studies and no important issues were identified 
during checking of the data. 
Baseline patient characteristics of the combined dataset are displayed in Table 1. There were a total of 
1,453 eligible patients and norepinephrine was the control in all four trials. Median age and APACHE II 
score were 64 years and 26 respectively. Approximately 71% were ventilated at baseline (Table 1). 
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Although just under 40% of patients had a stage 2 or greater AKI at baseline, only 3% were receiving RRT 
(Table 1). Vasopressin dosing was lower in VASST compared to the other trials (VASST: 0.01 to 0.03 
U/min, VANISH: up to 0.06 U/min, VANCS II: 0.01 to 0.06 U/min, Dunser et al.: up to 0.066U/min). The 
trial by Dunser et al. enrolled 48 patients in total but we only included the 15 patients with septic shock 
for our analysis.
Crude outcome data is displayed in Table 2. Overall 28-day mortality was 38% (49% when restricting to 
the 904 patients with a lactate >2mmol/l satisfying the septic shock 3.0 definition[30]) and varied 
between trials (VASST (37%), VANISH (29%), VANCS II (55%), Dunser et al. (60%)). For the primary 
outcomes, there was no evidence of an effect of vasopressin on 28-day mortality (relative risk (RR) 0.98, 
95% CI 0.86 to 1.12) or SAEs (RR 1.02, 95% CI 0.82 to 1.26). Both analyses had no evidence of significant 
between-trial heterogeneity (I2 0% and 8% respectively) and forest plots are shown in Figures 1a & 1b. 
Serious adverse events, stratified by type, are displayed in Table 3. Although the overall number of 
events was similar, the side effect profile between vasopressin and norepinephrine was different. 
Vasopressin led to more digital ischaemia (absolute risk difference (ARD) 1.7%, 95% CI 0.3% to 3.2%) but 
fewer arrhythmias (ARD -2.8%, 95% CI -0.2% to -5.3%). Mesenteric ischaemia and acute coronary 
syndrome events were similar between groups. 
For the secondary outcomes, vasopressin reduced the requirement for RRT (RR 0.86, 95% CI 0.74 to 
0.99) with no evidence of between-trial heterogeneity (I2 27%, see figure 1c). There was no evidence for 
an effect of vasopressin on any other secondary outcome (see Tables S2a in the supplementary 
Appendix). 
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There were no significant treatment covariate interactions in the a priori defined subgroups that we 
investigated (see Tables S4-7 in the supplementary Appendix). Forest plots stratified by subgroup for the 
two primary outcomes and for two exploratory secondary outcomes are shown in Figures 2 and 3 
respectively.  
In sensitivity analyses, there was no material difference in primary outcome results with a random-
effects specification or one-stage analyses (full results in Tables S2b, S3a and S3b in the supplementary 
Appendix). There was no material difference in the relative risk of 28-day mortality when using 
aggregate data from the five non-included studies where mortality was reported (see Figures S2 in the 
supplementary appendix). For secondary outcomes, there was no material difference in results with 
one-stage analyses but the reduced RRT requirement with vasopressin was non-significant with a 
random-effects specification (RR 0.83, 95% CI 0.67 to 1.01, see table S2b in the supplementary 
Appendix). Where skewed continuous data were transformed to approximate normality, the only 
material difference in results pertained to duration of shock (defined as an ongoing requirement for 
vasopressors). Here, vasopressin consistently demonstrated a longer duration of shock in all patients 
(1.2 hours, 95% CI 1.1 to 1.4) and in only survivors (1.2 hours, 95% CI 1.0 to 1.4) that was statistically 
though not clinically significant (median shock duration in the total population was 50 hours 
(interquartile range (IQR) 28 to 91 hours)), see Table S8 and the Addendum to Table S8 in the 
supplementary Appendix for further details. 
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DISCUSSION 
This is the first individual patient data meta-analysis of vasopressin in septic shock and there are four 
main findings. First, we found no evidence of a statistically significant reduction in 28-mortality with the 
use of vasopressin therapy in adults with septic shock. In our analysis, observed 95% CIs were consistent 
with an effect that ranges between a 14% relative reduction and a 12% relative increase in the risk of 
28-day mortality with vasopressin therapy. Second, vasopressin appears safe with regard to serious 
adverse events overall and in all planned subgroups but with a different side effect profile to 
norepinephrine borne out by more digital ischaemia and fewer arrhythmias. Third, there is weak 
evidence for vasopressin resulting in a reduced requirement for RRT. Fourth, we had hypothesized that 
that there might be beneficial effects of vasopressin therapy in specific sub-groups but the subgroup 
interactions were not statistically significant although the 95% confidence intervals imply considerable 
uncertainty. 
Comparing our findings to the existing literature requires caution for several reasons. Most existing non-
IPD meta-analyses assess not only vasopressin but also its analogues and these are assessed in 
distributive shock states other than just sepsis (e.g. vasoplegia post cardiac surgery). Also, the as yet 
unpublished VANCS II trial has not been included in any meta-analyses to date [24]. McIntyre and 
colleagues found a reduced 28-day mortality in the subgroup of septic trials [31]. However, these trials 
also included terlipressin and limiting to only vasopressin resulted in a non-significant estimate. 
Vasopressin did not have a material impact on ICU or hospital length of stay and this was in line with our 
results. A recent non-IPD meta-analysis by Nedel et al. found no significantly reduced incidence of RRT 
in the subgroup of septic patients receiving vasopressin (OR 0.75, 95% CI 0.54 to 1.04) but the effect 
estimate was broadly similar to ours [32]. The variation in event rates among the four included trials is 
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not unexpected given the different inclusion/exclusion criteria and trial timeframes that they 
encompass [33].  
The high number of critical care trials that have found no mortality benefit for a proposed intervention 
has resulted in increasing attention toward enrichment strategies and identification of specific 
subgroups that disproportionately benefit from a therapy. Our IPD meta-analysis did not show 
significant interactions in the subgroups. In a re-analysis of the VASST trial, Russell and colleagues 
assessed the impact of the new septic shock 3.0 definitions on the original trial results [34]. They found 
that vasopressin was not efficacious in the new septic shock 3.0 cohort but was beneficial in patients 
with a lactate level ≤2 mmol/l. Bhatraju et al. investigated the response to vasopressin in two distinct 
AKI sub-phenotypes. 328 patients from the VASST trial who had IL-8, Ang-1 and Ang-2 measured were 
classified into two groups with a significantly improved 90-day mortality only found in one of the groups 
[35]. However, Antcliffe and colleagues performed a post-hoc analysis of 176 VANISH trial patients with 
blood samples enabling categorisation into two groups according to their transcriptomic sepsis response 
signatures and found no significant interaction between vasopressin/norepinephrine and 28-day 
mortality for the two groups [36]. These studies highlight the differential responses to vasopressin for 
some but not all phenotypes.  
The data on serious adverse events also merits attention. It may surprise clinicians that vasopressin, at 
these low doses, does not increase the incidence of mesenteric ischemia. Vasopressin results in a 
decreased incidence of arrhythmias, possibly by decreasing the use of adrenergic vasopressors. This 
result is consistent with the SOAP2 trial where dopamine led to more arrhythmias than norepinephrine 
(dopamine has far greater beta-adrenergic activity than norepinephrine) [2]. Our findings provide 
actionable evidence for clinicians when choosing a vasopressor for septic shock patients: greater 
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concern for arrhythmia will favour vasopressin while concern about digital ischaemia may favour 
norepinephrine.  
Our findings have several implications. First, they may inform future versions of the Surviving Sepsis 
Campaign guidelines which currently recommend vasopressin only as an adjunct agent [13]. In practice 
this means that vasopressin is often used only as a rescue therapy. Additional guidance could 
recommend earlier use in those with dysrhythmias or a tachycardia. Second, our results agree with the 
finding of reduced RRT use initially identified in the VANISH trial (although the overall evidence is weak 
considering the sensitivity analysis that does not achieve statistical significance and the multiple 
secondary outcomes assessed in this analysis) [12]. Therefore, this finding should be viewed as 
hypothesis generating only. RRT is an expensive critical care therapy [37] and future trials should 
incorporate health economic assessments that investigate the cost effectiveness of vasopressin in this 
regard. Third, long term mortality may be a more appropriate outcome for future vasopressin trials (at 
least 90 days). The ubiquitous provision of RRT in modern intensive care units ensures that renal failure 
is rarely a direct, early cause of mortality but renal injury may contribute to downstream longer term 
effects such as secondary episodes of sepsis and spiralling multi-organ failure which are only apparent in 
mortality beyond the first month [38, 39]. 
The main strengths of our study are: a systematic and comprehensive search (with pre-published 
protocol and analysis plan), the explicit inclusion of only randomised trial data, collection of individual 
patient data with which to facilitate standardised subgroup analyses and the use of models for assessing 
treatment-covariate interactions that accounted for aggregation bias where applicable. Our findings 
must also be considered in light of several limitations. First, not all trials reported data on every 
outcome of interest. Second, there are multiple comparisons with no adjustment made. Third, there 
were five trials that may potentially have provided additional data but that we excluded due to lack of 
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further information from study authors [8, 26-29]. Our analysis included 1,453 patients from a total pool 
of 1,975 (74%) if these five trials had also been included. As mentioned in the results, four of the studies 
have very small sample sizes [8, 26-28] and the fifth remains unregistered and unpublished [29]. Only 
one of these five trials included data on RRT requirement [8]. It is unclear how inclusion of data from 
these studies may have altered our results. Fourth, the trials included span 14 years in which there have 
been major shifts in the management of septic shock that may have differentially affected trial 
populations [40, 41]. 
Conclusions 
We found vasopressin therapy in septic shock had no effect on 28-day mortality although the 
confidence intervals are wide. It appears safe but with a different side effect profile to norepinephrine. . 
The finding of reduced RRT should be interpreted cautiously given the multiple secondary outcomes 
assessed and the fact that the result was not robust to sensitivity analyses. Future trials should focus on 
long term outcomes in select patient groups, as well as incorporating cost effectiveness analyses with 
regard to possible reduced RRT requirements.
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Figure legends 
Figure 1. Forest plot of primary outcomes (a) 28-day mortality, (b) serious adverse events and secondary 
outcome (c) requirement for renal replacement therapy (RRT).
Figure 2. Subgroup analysis for primary outcomes (28-day mortality and serious adverse events).
Figure 3. Subgroup analysis for exploratory secondary outcomes (90-day mortality and requirement for 
renal replacement therapy (RRT)).
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Table 1. Patient characteristics in combined individual patient dataset.
Characteristic 
Vasopressin
(n=735)
Norepinephrine
(n=718) Total (n=1,453)
Age - yr, median (IQR) 63 (52-73) 64 (52-74) 64 (52-73) 
Male - no. (%) 431 (58.6) 428 (59.6) 859 (59.1) 
Caucasian ethnicity - no. (%) 617 (84.0) 613 (85.4) 1230 (84.7) 
APACHE II score, median (IQR) 26 (21-31) 26 (21-31) 26 (21-31) 
Physiological variables, median (IQR)
Heart rate (bpm) 100 (85-113) 99 (85-114) 99 (85-114) 
Mean arterial pressure (mmHg) 70 (63-77) 70 (63-77) 70 (63-77) 
Lactate (mmol/l) 2.4 (1.5-4.1) 2.5 (1.5-4.7) 2.4 (1.5-4.6) 
PaO2/FiO2 ratio (mmHg) 196 (134-296) 200 (134-286) 198 (134-290) 
Creatinine (μmol/l) 138 (87-240) 140 (86-238) 140 (86-239) 
Bilirubin (μmol/l) 22 (11-49) 22 (11-48) 22 (11-49) 
Platelets (x1000/μl) 162 (85-270) 169 (92-259) 165 (88-263) 
GCS, median (IQR) 12 (6-15) 13 (6-15) 12 (6-15) 
Mechanical ventilation - no. (%) 519 (70.6) 518 (72.1) 1037 (71.4) 
Renal replacement therapy - no. (%) 22 (3.0) 21 (2.9) 43 (3.0) 
Time to study drug (hrs), median (IQR) 6.2 (3.2-14.1) 5.8 (3-12.9) 6 (3-13.5) 
Norepinephrine equivalent dose (μg/min), 
median (IQR) 12 (6.9-24) 14 (7.6-25) 13.1 (7-25) 
AKI severity - no. (%) 
No AKI or stage 1 425 (60.5) 426 (61.0) 851 (61.3) 
Stage 2 or 3 277 (39.5) 260 (37.9) 537 (38.7) 
Trial - no. (%)
Dunser 2003 8 (1.0) 7 (1.0) 15 (1.0) 
VASST 2008 397 (54.0) 382 (53.2) 779 (53.6) 
VANISH 2016 205 (27.9) 204 (28.4) 409 (28.2) 
VANCS II 2018 125 (17.0) 125 (17.4) 250 (17.2) 
Continuous data are median (IQR), categorical variables are N (%).  
Abbreviations 
AKI – Acute kidney injury; APACHE – Acute Physiology and Chronic Health Evaluation; CRP – C-reactive 
protein; GCS – Glasgow coma scale; IQR – interquartile range. 
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Table 2. Primary and secondary outcomes. 
OUTCOME Vasopressin Norepinephrine Total Patients 
Data 
availability 
PRIMARY 
28-day mortality, no. / 
total (%) 278 / 733 (37.9) 277 / 718 (38.6) 555 / 1451 (38.3) 1451 99.9%
SAEs, no. / total (%) 124 / 735 (16.9) 120 / 718 (16.7) 244 / 1453 (16.8) 1453 100.0%
SECONDARY 
90-day mortality no. / 
total (%) 267 / 525 (50.9) 287 / 511 (56.2) 554 / 1036 (53.5) 1036 71.3%
RRT requirement, no. / 
total (%) 215 / 735 (29.3) 243 / 717 (33.9) 458 / 1452 (31.5) 1452 99.9%
Duration of RRT (days), 
median (IQR)
All patients 3 (2 to 7) 3 (2 to 8) 3 (2 to 7) 151 27.1%
Survivors 4 (2 to 8) 5 (2 to 9) 4 (2 to 8) 74 
Non-survivors 2 (1 to 7) 3 (2 to 7) 3 (2 to 7) 77 
Duration of shock (hrs), 
median (IQR)
All patients 56 (32 to 97) 47 (25 to 87) 50 (28 to 91) 959 66.0%
Survivors 56 (36 to 97) 47 (26 to 87) 51 (30 to 91) 734 
Non-survivors 57 (27 to 102) 44 (22 to 87) 48 (23 to 91) 223 
Duration of ventilation
(days), median (IQR)
All patients 3 (2 to 9) 3 (2 to 11) 3 (2 to 10) 393 31.3%
Survivors 5 (2 to 11) 4 (2 to 13) 5 (2 to 12) 225 
Non-survivors 3 (1 to 5) 3 (2 to 6) 3 (1 to 5) 168 
Renal failure free days 
to day 28 (days), 
median (IQR) 23 (6 to 28) 23 (5 to 28) 23 (5 to 28) 1433 98.6%
Shock free days to day 
28 (days), median (IQR) 19 (1 to 24) 19 (1 to 25) 19 (1 to 25) 1434 98.7%
Ventilator free days to 
day 28 (days), median 
(IQR) 13 (1 to 24) 13 (0 to 24) 13 (0 to 24) 1423 97.9%
ICU free days to day 28
(days), median (IQR) 6 (0 to 22) 7 (0 to 23) 7 (0 to 22) 672 46.2%
ICU length of stay
(days), median (IQR) 
All patients 7 (4 to 12) 6 (3 to 13) 6 (3 to 12) 672 46.2%
Survivors 8 (5 to 15) 6 (3 to 13) 7 (4 to 13) 407 
Non-survivors 6 (2 to 10) 5 (2 to 11) 6 (2 to 10) 265 
Hospital length of stay
(days), median (IQR) 
All patients 14 (7 to 29) 14 (7 to 27) 14 (7 to 28) 655 45.1%
Survivors 23 (12 to 42) 20 (12 to 46) 23 (12 to 42) 399 
22
Non-survivors 7 (2 to 12) 6 (2 to 14) 6 (2 to 13) 256 
Abbreviations 
ICU – intensive care unit; RRT – renal replacement therapy; SAE – serious adverse events. 
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Table 3. Serious adverse events.
OUTCOME Vasopressin Norepinephrine ARD† (95% CI) 
Serious adverse events, no. / total (%) 124 / 735 (16.9) 120 / 718 (16.7) 0.2 (-3.7 to 4.0) 
Digital ischaemia 21 / 735 (2.9) 8 / 718 (1.1) 1.7 (0.3 to 3.2) 
Mesenteric ischaemia‡ 14 / 727 (1.9) 18 / 711 (2.5) -0.6 (-2.1 to 0.9) 
Acute coronary syndrome 18 / 735 (2.5) 17 / 718 (2.4) 0.1 (-1.5 to 1.7) 
Arrhythmia 39 / 735 (5.3) 58 / 718 (8.1) -2.8 (-0.2 to -5.3) 
† Percentage absolute risk difference ‡ The reduced denominator for mesenteric ischaemia is due to no available data on this serious adverse event in 
the trial by Dunser et al.
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